SGLT2 inhibitors and GLP-1 receptor agonists had limited unrestricted availability in Medicaid, present in 80% and 60% of FFS plans, and 67% and 48% of MCO plans, respectively.
Cross-Sectional (n=323)
Yes
There is substantial state variation and restricted access to cardioprotective SGLT2 inhibitors and GLP-1 receptor agonists for Medicaid enrollees, particularly in managed care plans.
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease and death, yet their availability in Medicaid is unclear. OBJECTIVE: To assess the unrestricted availability of SGLT2is and GLP-1 RAs, using dipeptidyl peptidase-4 inhibitors (DPP4is) as a benchmark. DESIGN: National cross-sectional study using publicly available data. SETTING: All 50 state Medicaid fee-for-service (FFS) plans and 273 nonelderly adult managed care organization (MCO) plans with comprehensive coverage in March 2024. PARTICIPANTS: Medicaid plans and enrollees with diabetes in those plans as of March 2024. MEASUREMENTS: Unrestricted availability was defined as having at least 1 medication in each class listed on the preferred drug list without prior authorization or step therapy. RESULTS: Of 50 FFS plans (including Washington, DC, and excluding 1 state, which had 5 MCO plans), 40 (80%) had unrestricted availability of SGLT2is, 30 (60%) of GLP-1 RAs, 41 (82%) of either, 29 (58%) of both, and 42 (84%) of DPP4is. Among 273 MCO plans (39 states; median, 6 plans range, 2 to 24 plans), 182 (67%) had availability of SGLT2is, 131 (48%) of GLP-1 RAs, 184 (67%) of either, 129 (47%) of both, and 204 (75%) of DPP4is. The proportion of MCO enrollees with availability varied markedly among states (SGLT2i range, 24% to 100%; GLP-1 RA range, 0% to 99%; DPP4i range, 41% to 100%). Primarily because of more MCO restrictions, 1.7 million enrollees (lower to upper bound, 1.33 million to 2.17 million enrollees; 25%) had restricted SGLT2i availability, 2.72 million (lower to upper bound, 2.12 million to 3.45 million; 40%) had restricted GLP-1 RA availability, and 1.5 million (lower to upper bound, 1.17 million to 1.90 million; 22%) had restricted DPP4i availability. Availability increased from 2020 to 2024, especially in FFS, but MCO GLP-1 RA availability has plateaued at below 60% since 2022. Tirzepatide was almost entirely restricted. LIMITATIONS: Diabetes enrollment was estimated using plan size and state and national prevalence data. The appropriateness of prior authorization restrictions was unknown. CONCLUSION: Many Medicaid enrollees have restricted access to cardioprotective medications, particularly in MCO plans for GLP-1 RA medications, with substantial state variation. Formulary coverage is a potential lever to increase availability of these medications while balancing pharmaceutical costs. PRIMARY FUNDING SOURCE: University of California, San Francisco, Action Research Center for Health Equity.
Makam et al. (Mon,) conducted a cross-sectional in Type 2 diabetes (n=323). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs. Dipeptidyl peptidase-4 inhibitors (DPP4is) was evaluated on Unrestricted availability (at least 1 medication in each class listed on the preferred drug list without prior authorization or step therapy). SGLT2 inhibitors and GLP-1 receptor agonists had limited unrestricted availability in Medicaid, present in 80% and 60% of FFS plans, and 67% and 48% of MCO plans, respectively.